Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
Conditions
- Hematopoietic and Lymphatic System Neoplasm
Interventions
- OTHER: Best Practice
- OTHER: Biomarker Analysis
- PROCEDURE: Biospecimen Collection
- OTHER: Questionnaire Administration
- DRUG: Ruxolitinib
Sponsor
City of Hope Medical Center
Collaborators